financetom
Business
financetom
/
Business
/
Bristol-Myers Squibb Unusual Options Activity For July 15
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bristol-Myers Squibb Unusual Options Activity For July 15
Jul 15, 2024 12:05 PM

Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb ( BMY ). Our analysis of options history for Bristol-Myers Squibb ( BMY ) revealed 10 unusual trades.

Delving into the details, we found 30% of traders were bullish, while 70% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $136,531, and 7 were calls, valued at $647,002.

Predicted Price Range

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $50.0 for Bristol-Myers Squibb ( BMY ) during the past quarter.

Analyzing Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Bristol-Myers Squibb's ( BMY ) options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Bristol-Myers Squibb's ( BMY ) substantial trades, within a strike price spectrum from $25.0 to $50.0 over the preceding 30 days.

Bristol-Myers Squibb Option Volume And Open Interest Over Last 30 Days

Noteworthy Options Activity:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
BMY CALL SWEEP BULLISH 01/16/26 $15.75 $15.6 $15.7 $25.00 $196.2K 2.9K 219
BMY CALL TRADE BEARISH 01/16/26 $15.9 $15.75 $15.75 $25.00 $155.9K 2.9K 113
BMY CALL SWEEP BULLISH 01/16/26 $16.0 $15.6 $16.0 $25.00 $87.7K 2.9K 30
BMY CALL SWEEP BEARISH 08/15/25 $1.64 $1.54 $1.64 $50.00 $86.6K 1.6K 0
BMY PUT SWEEP BEARISH 12/20/24 $8.35 $8.25 $8.35 $48.00 $49.2K 613 0

About Bristol-Myers Squibb

Bristol-Myers Squibb ( BMY ) discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Following our analysis of the options activities associated with Bristol-Myers Squibb ( BMY ), we pivot to a closer look at the company's own performance.

Present Market Standing of Bristol-Myers Squibb

With a trading volume of 9,670,839, the price of BMY is down by -1.12%, reaching $40.01.

Current RSI values indicate that the stock is is currently neutral between overbought and oversold.

Next earnings report is scheduled for 11 days from now.

What Analysts Are Saying About Bristol-Myers Squibb

A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $41.0.

An analyst from Barclays has decided to maintain their Equal-Weight rating on Bristol-Myers Squibb ( BMY ), which currently sits at a price target of $41.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb ( BMY ) with Benzinga Pro for real-time alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vanguard settles litigation over inflated mutual fund tax bills
Vanguard settles litigation over inflated mutual fund tax bills
Aug 7, 2025
(Reuters) -Vanguard Group settled a lawsuit accusing the mutual fund giant of saddling investors in its popular target-date funds with inflated tax bills, after a federal judge rejected an earlier settlement. In a filing on Thursday in Philadelphia federal court, Vanguard and the investors said they agreed in principle following private mediation to resolve all claims. They plan by September...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Vanguard settles litigation over inflated mutual fund tax bills
Vanguard settles litigation over inflated mutual fund tax bills
Aug 7, 2025
Aug 7 (Reuters) - Vanguard Group settled a lawsuit accusing the mutual fund giant of saddling investors in its popular target-date funds with inflated tax bills, after a federal judge rejected an earlier settlement. In a filing on Thursday in Philadelphia federal court, Vanguard and the investors said they agreed in principle following private mediation to resolve all claims. They...
Olin Insider Bought Shares Worth $373,956, According to a Recent SEC Filing
Olin Insider Bought Shares Worth $373,956, According to a Recent SEC Filing
Aug 7, 2025
02:58 PM EDT, 08/07/2025 (MT Newswires) -- Marc Ehrhardt, Vice President & President, Corporate Development, on August 06, 2025, executed a purchase for 20,000 shares in Olin (OLN) for $373,956. Following the Form 4 filing with the SEC, Ehrhardt has control over a total of 20,000 common shares of the company, with 20,000 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/74303/000007430325000115/xslF345X05/wk-form4_1754592624.xml Price:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved